Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
KORU Medical SystemsKRMD -0.31%78 Debt-to-EBITDA is 0.99 as of Jun. 2026. GuruFocus rates KRMD with a GF Score™ of 78/100 and a GF Value™ of $4.01 (Modestly Undervalued). Among 474 Medical Devices & Instruments companies, KORU Medical Systems ranks worse than 210970.25% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for KORU Medical Systems's Debt-to-EBITDA or its related term are showing as below:
KRMD'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.84 Med: -0.47 Max: 0.15
Current: -3.84
During the past 13 years, the highest Debt-to-EBITDA Ratio of KORU Medical Systems was 0.15. The lowest was -3.84. And the median was -0.47.
KRMD's Debt-to-EBITDA is ranked worse than 100% of 474
companies
in the Medical Devices & Instruments industry
Industry Median: 1.595
vs KRMD: -3.84
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
KORU Medical Systems Debt-to-EBITDA Related Terms
KORU Medical Systems Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for KORU Medical Systems's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KRMD vs PDEX, EMBC, UTMD: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, KORU Medical Systems's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
KORU Medical Systems Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, KORU Medical Systems's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where KORU Medical Systems's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.
KORU Medical Systems (KRMD) has a Debt-to-EBITDA of 0.99 as of Jun. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on KORU Medical Systems. According to the industry distribution chart, KORU Medical Systems ranks #999999 out of 474 companies in the Medical Devices & Instruments industry.
Is KORU Medical Systems' Debt-to-EBITDA too high?
KORU Medical Systems' current Debt-to-EBITDA is 0.99. The Medical Devices & Instruments industry median Debt-to-EBITDA is 1.60. KORU Medical Systems' value of 0.99 is 37.9% below this industry median. Based on the distribution chart, KORU Medical Systems ranks #999999 out of 474 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, KORU Medical Systems has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does KORU Medical Systems' Debt-to-EBITDA compare to PDEX and EMBC?
According to the Medical Devices & Instruments industry distribution chart, KORU Medical Systems ranks #999999 out of 474 companies for Debt-to-EBITDA. This places KORU Medical Systems in the lower half of its industry. The industry median Debt-to-EBITDA is 1.60. KORU Medical Systems' value of 0.99 is 37.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.60, based on 474 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. KORU Medical Systems's current Debt-to-EBITDA of 0.99 is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on KORU Medical Systems. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. KORU Medical Systems's current Debt-to-EBITDA is 0.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is KORU Medical Systems stock overvalued right now?
Based on GuruFocus' analysis, KORU Medical Systems (KRMD) is currently considered Modestly Undervalued. The stock's GF Value™ is $4.01, compared to a current price of $3.21 — trading 20% below its estimated fair value. The current Debt-to-EBITDA is 0.99 and 37.9% below the Medical Devices & Instruments industry median of 1.60. KORU Medical Systems' overall GF Score™ is 78/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For KORU Medical Systems (KRMD), the current Debt-to-EBITDA is 0.99 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is KORU Medical Systems (KRMD) Overvalued in 2026?
Based on GuruFocus' analysis, KORU Medical Systems stock appears to be undervalued.
The current stock price of $3.21 is trading 20% below its estimated GF Value™ of $4.01.
GuruFocus considers KORU Medical Systems to be Modestly Undervalued.
Key valuation signals for KRMD:
Debt-to-EBITDA: 0.99
GF Value™: $4.01 vs. price of $3.21 (20% below fair value)
Industry Position: 37.9% below the Medical Devices & Instruments median (#999999 of 474)
No single metric tells the full story. See the KRMD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
KORU Medical Systems Inc develops, manufactures, and commercializes large volume subcutaneous infusion solutions for the subcutaneous drug delivery market. Its product portfolio focuses on mechanical infusion devices, including the FREEDOM60 and FreedomEdge syringe drivers, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company operates as one segment. Its revenue streams are: Domestic Core, International Core and Pharma services and clinical trials. The majority of the company's revenue is derived from the Domestic Core business, which consists of sales of its syringe drivers, tubing and needles. Geographically, its revenues are predominantly derived from the United States.
78GF Score
Get the complete analysis for KRMD
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KRMD has been successfully added to your 
